Using bioinformatics technology to mine the expression of serum exosomal miRNA in patients with traumatic brain injury

Huang, Xintao; Xu, Xiufeng; Wang, Yi; Yang, Yajun; Yao, Tianle; Bai, Rui; Pei, Xile; Bai, Feirong; Li, Panpan

doi:10.3389/fnins.2023.1145307

Cited by 9 publications

(2 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this review, we have evaluated the existing evidence of mir-124 involvement in TBI, highlighting the different models that have been used to assess this, as well as the contradictory findings that have been reported. According to mounting clinical findings, various miRNAs have been found to be abnormally expressed in patients with TBI, such as miR-21, miR-137, miR-133, miR-199, miR-204, and miR-519 ( Huang et al, 2023 ; Lin et al, 2023 ). Among the sixteen included studies, three clinical trials ( O’Connell et al, 2020 ; Vuokila et al, 2020b ; Shi et al, 2022 ) provided the clinical significance of miR-124 in TBI.…”

Section: Discussion Of the Existing Evidencementioning

confidence: 99%

Roles of microRNA-124 in traumatic brain injury: a comprehensive review

Wu,

He,

et al. 2023

Front. Cell. Neurosci.

View full text Add to dashboard Cite

Traumatic brain injury (TBI) is a prominent global cause of mortality due to the limited availability of effective prevention and treatment strategies for this disorder. An effective molecular biomarker may contribute to determining the prognosis and promoting the therapeutic efficiency of TBI. MicroRNA-124 (miR-124) is most abundantly expressed in the brain and exerts different biological effects in a variety of diseases by regulating pathological processes of apoptosis and proliferation. Recently, increasing evidence has demonstrated the association between miR-124 and TBI, but there is still a lack of relevant literature to summarize the current evidence on this topic. Based on this review, we found that miR-124 was involved as a regulatory factor in cell apoptosis and proliferation, and was also strongly related with the pathophysiological development of TBI. MiR-124 played an essential role in TBI by interacting with multiple biomolecules and signaling pathways, such as JNK, VAMP-3, Rela/ApoE, PDE4B/mTOR, MDK/TLR4/NF-κB, DAPK1/NR2B, JAK/STAT3, PI3K/AKT, Ras/MEK/Erk. The potential benefits of upregulating miR-124 in facilitating TBI recovery have been identified. The advancement of miRNA nanocarrier system technology presents an opportunity for miR-124 to emerge as a novel therapeutic target for TBI. However, the specific mechanisms underlying the role of miR-124 in TBI necessitate further investigation. Additionally, comprehensive large-scale studies are required to evaluate the clinical significance of miR-124 as a therapeutic target for TBI.

show abstract

Section: Discussion Of the Existing Evidencementioning

confidence: 99%

Roles of microRNA-124 in traumatic brain injury: a comprehensive review

Wu,

He,

et al. 2023

Front. Cell. Neurosci.

View full text Add to dashboard Cite

show abstract

“…Recently, miRNAs from EVs have been associated with several neurological ailments, including psychiatric [19] and neurodegenerative disorders [20]. Indeed, EV miRNAs are altered in TBI [21,22] and epilepsy [16,23].…”

Section: Introductionmentioning

confidence: 99%

miR-9-5p is Downregulated in Serum Extracellular Vesicles of Patients Treated with Biperiden After Traumatic Brain Injury

Villena-Rueda,

Kajitani,

Ota

et al. 2024

Mol Neurobiol

View full text Add to dashboard Cite

Traumatic brain injury (TBI) is a prevalent and debilitating condition, which often leads to the development of post-traumatic epilepsy (PTE), a condition that yet lacks preventive strategies. Biperiden, an anticholinergic drug, is a promising candidate that has shown e cacy in murine models of PTE. MicroRNAs (miRNAs), small regulatory RNAs, can help in understanding the biological basis of PTE, and act as TBI-and PTE-relevant biomarkers that can be detected peripherally, as they are present in extracellular vesicles (EVs) that cross the blood brain barrier. This study aimed to investigate miRNAs in serum EVs from patients with TBI, and their association with biperiden treatment and PTE. Blood samples of 37 TBI patients were collected 10 days after trauma and treatment initiation in a double-blind clinical trial. A total of 18 patients received biperiden, with 3 subjects developing PTE, and 19 received placebo, with 2 developing PTE. Serum EVs were characterized by size distribution and protein pro ling, followed by high-throughput sequencing of the EV miRNome. Differential expression analysis revealed no signi cant differences in miRNA expression between TBI patients with and without PTE. Interestingly, miR-9-5p displayed decreased expression in biperiden-treated patients compared to the placebo group. This miRNA regulates genes enriched in stress response pathways, including axonogenesis and neuronal death, relevant to both PTE and TBI. These ndings suggest serum miR-9-5p as a possible marker for biperiden treatment, which may play a role in TBI resolution.

show abstract

Exploring New and Promising Genetic Biomarkers for Evaluating Traumatic Brain Injuries: A Case-Control Study

Rabou,

Zayed,

Fahim

et al. 2024

Neurochem Res

View full text Add to dashboard Cite

Traumatic brain injury (TBI) is a common cause of morbidity and death in all age groups, with an estimated 50 million people having brain injury due to trauma each year. Accurate blood-based biomarkers are needed to assist with diagnosis of patients across the spectrum of time and severity. Our objectives were to explore the diagnostic precision of time- and severity- related four blood-based biomarkers: AKT3, GSK-3β, hsa-miR-16-5p, and MALAT-1 for TBI for the purpose of diagnosis, prognosis, and follow-up. 40 samples were recruited as the following: 30 TBI patients and 10 healthy volunteers as controls with matched age and sex. They were divided according to the Glasgow Coma Scale into mild (mTBI), moderate (modTBI), and severe(sTBI) TBI. Blood samples were withdrawn at entry, and after 5 and 30 days, RT-PCR was used for measuring the expression level. The results showed upregulated expression levels of AKT3, hsa-miR-16-5p and significantly downregulated expression levels of GSK-3β in TBI patients compared to controls at all timings measured. mTBI patients showed a higher expression level of hsa-miR-16-5p compared with modTBI, and sTBI patients. MALAT-1 level showed a significant increase in severe cases only. We concluded that AKT3, hsa-miR-16-5p, and GSK-3β are excellent diagnostic biomarkers in TBI patients at initial assessment, as well as at 5 and 30 days following the injury. Moreover, MALAT-1 had good diagnostic value in sTBI patients, and its prognostic value extends to 30 days. GSK-3β was an excellent biomarker for detecting mTBI.

show abstract

Using bioinformatics technology to mine the expression of serum exosomal miRNA in patients with traumatic brain injury

Cited by 9 publications

References 39 publications

Roles of microRNA-124 in traumatic brain injury: a comprehensive review

Roles of microRNA-124 in traumatic brain injury: a comprehensive review

miR-9-5p is Downregulated in Serum Extracellular Vesicles of Patients Treated with Biperiden After Traumatic Brain Injury

Exploring New and Promising Genetic Biomarkers for Evaluating Traumatic Brain Injuries: A Case-Control Study

Contact Info

Product

Resources

About